Algeta Concludes Agreements for the Manufacture and Supply of Alpharadin for Future Commercial Sale
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Algeta ASA has announced it has concluded two agreements for the manufacture and supply of Alpharadin for future commercial sale. Alpharadin (radium-223) is a novel, targeted alpha-pharmaceutical in clinical trials for treating bone metastases in cancer patients.
The signing of these agreements triggers a EUR 5 million milestone payment from Bayer Schering Pharma (Bayer), Algeta’s development and commercial partner for Alpharadin.
The first agreement, with Bayer, provides that Algeta will be the exclusive supplier of Alpharadin for future commercial sale.
The second agreement sees Algeta significantly extend its collaboration with Oslo’s Institute for Energy Technology (IFE), which currently manufactures Alpharadin for Algeta/Bayer’s ongoing ALSYMPCA phase III study and clinical trials in other cancer indications.
Under the terms of this second agreement, IFE, in conjunction with Algeta, will commence an expansion of the existing Alpharadin production facility at IFE. The upgrade, which will be paid for by Algeta, will create a manufacturing facility to supply the expected commercial demand around the world following approval and launch.
Andrew Kay, Algeta’s President and CEO said: “IFE has proved to be an excellent manufacture and supply partner of Alpharadin for all our clinical trials to date. We look forward to continuing our work together with IFE to secure the future clinical and commercial supply of Alpharadin.”
He added: “Algeta and IFE have developed world-leading expertise in the production of the alpha-emitters that underpin our alpha-pharmaceutical platform. As a consequence, the new, state-of-the-art facility will also provide an important advantage to Algeta as it looks to advance its Thorium platform. The conclusion of these agreements, therefore, is a very positive development for Algeta.”
The signing of these agreements triggers a EUR 5 million milestone payment from Bayer Schering Pharma (Bayer), Algeta’s development and commercial partner for Alpharadin.
The first agreement, with Bayer, provides that Algeta will be the exclusive supplier of Alpharadin for future commercial sale.
The second agreement sees Algeta significantly extend its collaboration with Oslo’s Institute for Energy Technology (IFE), which currently manufactures Alpharadin for Algeta/Bayer’s ongoing ALSYMPCA phase III study and clinical trials in other cancer indications.
Under the terms of this second agreement, IFE, in conjunction with Algeta, will commence an expansion of the existing Alpharadin production facility at IFE. The upgrade, which will be paid for by Algeta, will create a manufacturing facility to supply the expected commercial demand around the world following approval and launch.
Andrew Kay, Algeta’s President and CEO said: “IFE has proved to be an excellent manufacture and supply partner of Alpharadin for all our clinical trials to date. We look forward to continuing our work together with IFE to secure the future clinical and commercial supply of Alpharadin.”
He added: “Algeta and IFE have developed world-leading expertise in the production of the alpha-emitters that underpin our alpha-pharmaceutical platform. As a consequence, the new, state-of-the-art facility will also provide an important advantage to Algeta as it looks to advance its Thorium platform. The conclusion of these agreements, therefore, is a very positive development for Algeta.”
